Abstract:Dong et al. present a novel approach to preoperative lymph node (LN) metastasis evaluation in rectal cancer. By integrating MRI radiomics with clinical data, they developed a machine learning model that surpasses traditional assessment methods in predicting LN metastasis, achieving a higher positive predictive value. The findings suggest that this approach could significantly aid in tailoring more precise treatment strategies, emphasizing the clinical utility of combining radiomics with conventional clinical data. This research exemplifies how precision medicine can enhance non-invasive diagnostic accuracy and assist in tailoring treatment strategies, thus improving management for patients with colorectal cancer.Building upon this theme of innovative diagnostic techniques, O'Shea et al. introduce an advancement in integrating genomic testing into routine oncology practice. Their study presents a model, derived from comprehensive implementation research, provides a structured approach to improve access to genomic testing for Lynch syndrome. By addressing barriers such as funding, infrastructure, and role delineation, and proposing solutions like embedded genetic counselors and electronic medical record integration, this model aims to streamline genetic testing processes. Its successful implementation could serve as a blueprint for other hereditary cancer syndromes, facilitating broader adoption of precision medicine practices. This study aims to integrate precision medicine into routine oncology practice, ensuring that individuals with hereditary risks receive timely and accurate genetic testing and subsequent personalized care.Complementing these advancements in diagnostics and genetic testing, Brand et al. explore the potential of cytokine profiling to predict colorectal cancer risk in Lynch syndrome patients. By analyzing normal-appearing colorectal tissue, the study identifies immune signatures that distinguish LS patients with a history of CRC from those without. These findings suggest that immune microenvironment profiling could become a valuable tool in CRC risk assessment and prevention strategies, enabling more personalized surveillance and intervention approaches.While Brand et al. focus on risk prediction, another crucial aspect of personalized care for hereditary colorectal cancer syndromes is chemoprevention. In this vein, Mraz et al. provide valuable insights into how chemoprevention is widely discussed and applied, particularly in Lynch syndrome (LS) and familial adenomatous polyposis (FAP). There remains considerable variability in the specifics of these practices. Most professionals recommend aspirin for LS patients, albeit with no consensus on the optimal dosage. This heterogeneity underscores the need for standardized guidelines and further research to optimize chemoprevention strategies, considering individual patient factors to maximize benefits and minimize risks.As the field of chemoprevention continues to evolve, so too does our understanding of genetic risk factors. Highlighting this progression, Li et al. demonstrate the critical role of genetic testing in hereditary cancer syndromes through their identification of a novel splicing variant in the MSH2 gene. This study not only confirms the pathogenicity of the MSH2 c.793-1G>A variant through bioinformatics and functional assays but also underscores the importance of regular surveillance for mutation carriers. Such genetic insights are vital for early detection and prevention of CRC in at-risk populations. By confirming the pathogenicity of this variant, this study supports the role of precision medicine in identifying genetic mutations and highlights the need for regular surveillance and personalized risk assessment for mutation carriers.Moving from genetic risk factors to the broader molecular landscape of colorectal cancer, He et al. offer new perspectives on the molecular underpinnings of colon cancer through their exploration of cuproptosis-related genes. By identifying distinct molecular subtypes associated with different tumor microenvironment characteristics and treatment responses, their research contributes to the development of more tailored therapeutic strategies. This study exemplifies how precision medicine can guide the development of personalized treatment options for patients with hereditary predispositions to colon cancer, further emphasizing the importance of molecular profiling in advancing CRC care.These studies collectively underscore the rapidly evolving landscape of CRC diagnosis and treatment, driven by advancements in genomics, radiomics, and immunology. By presenting these diverse contributions, we aim to provide a comprehensive overview of how precision medicine is reshaping our approach to hereditary CRC syndromes. Looking ahead, it will be crucial to continue validating these findings through large-scale, multicenter studies and to develop standardized -Abstract Truncated-

Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence

Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives

Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration

Multi-omics based artificial intelligence for cancer research

Precision medicine and immunotherapy advances transforming colorectal cancer treatment

Advances in the application of colorectal cancer organoids in precision medicine

Editorial: Hereditary colorectal cancer syndromes and risk assessment in the era of precision medicine

Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Improving prediction of treatment response and prognosis in colorectal cancer with AI-based medical image analysis

Artificial Intelligence-Based Multi-Omics Analysis Fuels Cancer Precision Medicine.

Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology

Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer

Research and application of omics and artificial intelligence in cancer

Multi-omics insights into the interplay between gut microbiota and colorectal cancer in the "microworld" age

Radiomics in precision medicine for colorectal cancer: a bibliometric analysis (2013–2023)

A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes

From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine

Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for colorectal cancer

Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers

Integrating artificial intelligence techniques for advancements in colorectal cancer management: navigating past and predicting future direction